SEL ICB Lambeth Community Denosumab Service

Description

Provision of a community-based shared care service for the administration and monitoring of denosumab 60mg/ml for osteoporosis. The service will support patients in Lambeth (or registered with a Lambeth GP) who have been identified by secondary care as clinically appropriate for treatment in the community. The Provider will deliver blood monitoring, prescribing support, and timely administration of injections in accordance with the South East London Shared Care Agreement, while clinical responsibility remains with secondary care. Lot 1: This notice relates to the Lambeth Community Denosumab Service and is an intention to award a contract to the existing provider via Direct Award Process C. The service provides a community-based shared care pathway for patients prescribed denosumab 60mg/ml for the treatment of osteoporosis. Patients remain under the clinical responsibility of secondary care within South East London, in accordance with the South East London Shared Care Agreement for Denosumab. Secondary care will identify and refer a cohort of clinically appropriate patients for management in the community setting. The Provider will be responsible for delivering the community service, including required blood monitoring, prescribing support, and administration of denosumab injections at clinically appropriate intervals. The service is available to patients referred by secondary care who are registered with a GP in Lambeth or are Lambeth residents and who meet the eligibility criteria set out in the contract and Shared Care Agreement. The estimated contract value is £49,140 per annum. The contract duration is 6 months from 01/06/2026 to 30/11/2026, with an option to extend for a further 6 months at the discretion of the Authority, up to 31/05/2027. This is a direct award with no competition under the Provider Selection Regime (PSR) - Direct Award Process C. As such, no award criteria were applied. The contracting authority has determined that the existing provider will be awarded the contract on the basis that: The current provider is delivering the service to a satisfactory standard. There are no proposed changes to the existing contract terms. Continuity of care is essential for this patient cohort The provider continues to meet all relevant clinical, quality, and service requirements. The decision is made in accordance with PSR requirements for Direct Award Process C. Additional information: Procurement Route This contract is intended to be awarded under the Provider Selection Regime (PSR) - Direct Award Process C. Rationale for Direct Award The current provider is delivering the service to a satisfactory standard, and there are no proposed changes to the existing contract terms. Continuity of care is essential for this patient cohort. The provider continues to meet all relevant clinical, quality, and service requirements. Decision The Contracting Authority intends to award the contract to the existing provider in accordance with PSR Direct Award Process C.